Dec. 19, 2024 /PRNewswire/ -- CellFE ®, a disruptive life sciences company marketing non-viral, non-electroporative cell therapy manufacturing tools, today announced several strategic system ...
Development Services Span Tech Transfer, Process Assessment and Method Validation for Fill and Finish of NRS-033 for Planned Phase 2 ...
Will support clinical development of Nirsum’s lead development candidate, NRS-033.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback